Innoviva, Inc. INVA
Updated: 17 Jun 2026
No signal published yet
We already track Innoviva and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Innoviva, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Innoviva free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 16, 2026, Innoviva Specialty Therapeutics announced a licensing agreement with Dr. Reddy's Laboratories for the international distribution of the antibiotic XACDURO. The company also recently reported Q1 2026 revenue of $98 million, driven by its core royalty portfolio and growth in specialty product sales.
What Firelda Watch includes for Innoviva, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Innoviva, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Innoviva free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more